Uzedy Request Rep Jun 2026

Visit the Request a Representative page on the Teva HCP website. You will need to provide your professional contact information and NPI number to ensure you are matched with the local representative for your region.

| Factor | Shared Rep (e.g., with oral antipsychotic) | Dedicated Uzedy Rep | |--------|--------------------------------------------|----------------------| | | Diluted across multiple products | Focused: LAI conversion, copolymer tech, dosing flexibility | | Access pull-through | Minimal | Full-time prior auth support & nurse educator coordination | | Prescriber targets | 40-50 generalists | 15-20 high-value LAi prescribers (psychiatrists, hospitalists) | | Time to peak share | 9-12 months | 3-4 months | uzedy request rep

(risperidone) is an extended-release injectable suspension used for the treatment of schizophrenia in adults. As a newer long-acting injectable (LAI) antipsychotic entering a competitive market, the financial burden on patients and healthcare systems is a significant consideration. Consequently, the "Request for Rep" (often shorthand for Request for Repayment , Rebate , or Reimbursement Support ) is a critical administrative process for providers and patients to ensure access and affordability. Visit the Request a Representative page on the

For pharmacies and clinics, managing the "Rebate" is about backend revenue cycle management. This involves submitting utilization data to the manufacturer or Pharmacy Benefit Manager (PBM) to recover rebates promised in the contract. Uzedy’s unique value proposition (flexible dosing

: It carries a Boxed Warning regarding an increased risk of death in elderly patients with dementia-related psychosis. Clinical Resources

By optimizing these repayment and rebate processes, healthcare systems can ensure that innovative therapies like Uzedy are accessible to the populations that need them most.

This report requests the approval and deployment of a dedicated sales representative for in [Territory/Region]. Current market dynamics for long-acting injectable (LAI) antipsychotics favor first-to-market advantages; however, Uzedy’s unique value proposition (flexible dosing, proprietary copolymer technology, and reduced injection pain) requires specialized clinical selling. A dedicated rep is projected to increase market share by 8-12% within two quarters and convert 15-20 high-volume prescribers from oral risperidone and competitor LAIs (Invega Sustenna, Aristada, Abilify Maintena).